68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis

Alessio Imperiale, Vincent Poindron, Matias Martinez, Patrick Ohlmann, Thomas H. Schindler, Soraya El Ghannudi

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and 18F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to 18F-FDG uptake, which reflects nonspecific leukocyte infiltration, 68Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of 68Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive 18F-FDG PET/CT results.

Original languageEnglish
Pages (from-to)E416-E418
JournalClinical nuclear medicine
Volume45
Issue number9
DOIs
StatePublished - Sep 1 2020

Keywords

  • DOTATOC
  • FDG
  • PET
  • cardiac magnetic resonance
  • cardiac sarcoidosis

Fingerprint

Dive into the research topics of '68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis'. Together they form a unique fingerprint.

Cite this